European Psychiatry - Volume 33 - March 2016

730 / 812

S726 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805
4 Campo del Vescovo Union, Therapeutic Psychiatric Community, La
Spezia, Italy
∗ Corresponding author.
Introduction Limited research has been devoted to the subjective
impact of switching antipsychotic maintenance treatment (AMT)
from oral to LAI formulation in schizophrenia.
Objective To compare LAI AMT with oral AMT in terms of sub-
jective experience of treatment, taking into account the effects on
psychopathology.
Methods Twenty outpatients (7 males, mean age 40.55± 11.00
years) with remitted schizophrenia treated with either olanza-
pine or paliperidone and switching from oral to LAI AMT were
recruited before the switch (LAI-AMT group). A group of 20 remit-
ted schizophrenic subjects with oral AMT andmatched for themain
socio-demographic, clinical and treatment variables made up the
controls (oral-AMT group). All participants were assessed bymeans
of the PANSS and of the SWN-K at baseline (T0) and after 6 months
(T1).
Results Between T0 and T1, general psychopathology of the
PANSS and all but one of the SWN-K dimensions (except for “social
integration”), showed significantly higher percent improvements
in the LAI-AMT group compared to the oral-AMT group. After 6
months (T1), the LAI-AMT group showed significantly lower PANSS
total and general psychopathology scores, as well as higher mean
score of perceived “mental functioning” compared to the oral-
AMT group. Item analysis of the general PANSS at T1 showed
significant differences between the two groups in anxiety, ten-
sion, depression, guilt feelings, poor attention, and active social
avoidance.
Conclusions Our data on switching fromoral to LAI AMT in remit-
ted schizophrenia suggest a better efficacy of the latter in terms of
improvement of general psychopathology and subjective experi-
ence of treatment.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1181
LAI versus oral antipsychotic
treatment of schizophrenia: A
12-month prospective study on
patient’s attitude towards treatment
and quality of life
F. Pietrini ∗, A. Ballerini , I. Burian , B. Campone , F. Chiarello ,
E. Ciampi , E. Corsi , N. Ferruccio , M. Moneglia , L. Poli ,
A. Santangelo , S. Spitoni , V. Ricca
University of Florence, Department of Neuroscience, Psychology, Drug
Research and Child Health, section of Neuroscience, Florence, Italy
∗ Corresponding author.
Introduction It is still a matter of debate whether LAI antipsy-
chotics are able to significantly improve patient’s attitude towards
treatment.
Objective The aim of this 12-month observational study was to
investigate the impact of switching antipsychotic treatment from
oral to LAI formulation on patient’s attitude towards treatment and
quality of life.
Methods A total of 41 schizophrenic patients (25 males, mean
age 42.10 ± 11.88 years) were recruited. Patients were expected
not to need significant changes in concomitant treatments. All
patients were under a stabilized therapy with a single oral antipsy-
chotic (either olanzapine or paliperidone) and were switched to
the equivalent maintenance regimenwith the long-acting formula-
tion of the same antipsychotic (olanzapine pamoate or paliperidone
palmitate). Patients were assessed before the switch (T0), and after
6 (T1) and 12 months (T2) of LAI antipsychotic treatment by means
of the YMRS, MADRS, PANSS, DAI-10 and SF-36.
Results Our data evidenced an overall significant improvement
of psychopathology, adherence and quality of life over the 12-
month period (T0 vs. T2). In particular, while all of the measures
significantly improved in the first semester (T0 vs. T1), only YMRS,
positive PANSS and DAI-10 improved both in the first and in the
second semester (T1 vs. T2), indicating an additional advantage of
a prolonged LAI treatment on these clinical dimensions.
Conclusions The switch from oral to long-acting antipsychotic
treatment may provide considerable advantages in improving
patient’s attitude towards (and therefore adherence to) treatment.
Part of this improvement could be related with a better efficacy on
psychopathology and quality of life.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1182
Depot medication and compulsory
treatment
A. Poc¸ as ∗, S. Azenha
1 Centro Hospital de Leiria, Servic¸ o de Psiquiatria, Braga, Portugal
2 Hospital de Braga, Servic¸ o de Psiquiatria, Braga, Portugal
∗ Corresponding author.
Introduction It is estimated that 90% of patients with schizophre-
nia only adhere partially to the treatment. The use of depot
medication is an option for patients with schizophrenia rather
using it in voluntary or compulsory treatment.
Objectives and aims We tried to check on differences in the
outpatient treatment of schizophrenia among patients receiving
compulsory (involuntary outpatient commitment [IOC]) and vol-
untary treatment and analyzed the outcomes in patients in IOC
taking oral versus depot antipsychotics.
Method We assessed and compared socio-demographic and clin-
ical features, therapeutics likelihood ofmedication adherence (with
Medication adherence rating scale [MARS]), personal and social
performance (PSP) scale and predominant kind of symptoms (with
Positive and Negative Syndrome Scale [PANSS]).
Results and conclusion All patients were taking antipsychotics,
and 63% of compulsive and 33% of volunteers were taking oral
and injectable antipsychotics simultaneously. We observed that
21% of compulsive and 30% of the volunteers were simultaneously
doing typical and atypical antipsychotics. Depot medication was
being taken by 84% of patients in IOC and in just 54% of volunteers.
We do not find statistically significant differences in outcomes of
patients in IOC with injectable medication ( n = 16) compared to
those who were only with oral medication (n = 3), in terms of prob-
ability of adherence to medication, functionality or predominant
symptomatic type. Compulsive patients had higher use of typical
antipsychotics, perhaps in order to have a more sedative effect
in patients with more severe disease. The prevalence of atypical
antipsychotics in volunteers focuses on the need of a better cogni-
tive performance and functionality.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1183
Catatonic schizophrenia vs anti-NMDA
receptor encephalitis – A video case
report
A. Ponte ∗, J. Gama Marques , L. Carvalhão Gil , C. Nobrega ,
S. Pinheiro , A. Brito
1 Centro Hospitalar Psiquiátrico de Lisboa, Psychiatry, Lisbon,
Portugal
2 Centro Hospitalar Psiquiátrico de Lisboa, Neurology, Lisbon,
Portugal